The DNA manufacturing market size was estimated at USD 6.55 billion in 2025 and is projected to increase from USD 7.72 billion in 2026 to approximately USD 33.99 billion by 2035, growing at a CAGR of 17.9% from 2026 to 2035. The DNA manufacturing market is driven by the rise in gene therapy and advanced therapeutics, the expansion of mRNA vaccine technology, and growing investment in biopharma and synthetic biology.
DNA manufacturing comprises the customized production of synthetic and plasmid DNA molecules, which are essential tools for modern biotech research, gene therapies, mRNA vaccines, and molecular diagnostics. The key advantages include faster, automated, and more accurate synthetic production, which reduces dependency on traditional, time-consuming bacteria-based methods. The market growth is driven by surging demand for advanced cell and gene therapies, the rise of personalized medicine, and innovations in gene-editing tools such as CRISPR.
Moving away from traditional, slow cell-based fermentation, the industry is adopting enzymatic synthesis, such as polymerase-based methods, to produce high-purity synthetic DNA faster and more efficiently. This method is particularly suited for creating long, complex sequences with fewer impurities, making it ideal for mRNA therapeutics and gene therapies.
The surging development of gene therapies, viral vectors, and mRNA vaccines has created massive demand for high-quality, good manufacturing practice-compliant plasmid DNA. As more therapeutic products advance into late-stage clinical trials and commercialization, companies are investing in expanding their GMP capacity to prevent supply bottlenecks.
To overcome manual limitations and improve speed, manufacturers are increasingly using automated systems for synthesis, purification, and quality control. These high-throughput platforms, such as automated benchtop synthesizers, allow for the rapid creation of DNA libraries and customized sequences, reducing costs and accelerating research and development timelines.
AI and ML are revolutionizing the DNA manufacturing industry by accelerating synthesis, improving accuracy, and reducing costs through intelligent sequence optimization and automated design. Machine learning algorithms can predict and resolve synthesis bottlenecks for complex sequences, increasing successful production rates while minimizing wasteful, iterative trial-and-error workflows. These technologies allow for the rapid, high-throughput creation of custom DNA for applications like mRNA vaccines, gene therapy, and synthetic biology, often reducing development timelines by up to 25% or more.
| Report Coverage | Details |
| Market Size in 2026 | USD 7.72 Billion |
| Market Size by 2035 | USD 33.99 Billion |
| Growth Rate From 2026 to 2035 | CAGR of 17.9% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | Type, Grade, Application, End use, Region |
| Market Analysis (Terms Used) | Value (USD Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Charles River Laboratories; VGXI, Inc.; Danaher (Aldevron); Thermo Fisher Scientific; Lonza; GenScript; Catalent; Wuxi AppTec; Kaneka Corp.; Eurofins Genomics |
Surging Demand for Cell and Gene Therapies
With the rapid increases in FDA-approved therapies and clinical trials, particularly for CAR-T cell therapies and in vivo gene therapies, there is an exponential need for large-scale, GMP-grade DNA to produce viral vectors and genetic constructs. This rising demand for genetic medicine has intensified the need for specialized contract development and manufacturing organizations (CDMOs) to accelerate production, driving investment in DNA synthesis technologies. The expansion of RNA-based vaccines and emerging gene-editing tools, such as CRISPR-Cas systems, requires custom-designed, high-purity DNA sequences, propelling the market towards advanced, scalable manufacturing solutions.
Tightening Regulatory and Biosecurity Frameworks
The market growth is hindered by introducing significant compliance bottlenecks, which increase the cost and time-to-market for custom sequences. Stringent biosecurity measures, such as mandatory sequence screening, require companies to invest heavily in specialized software and personnel, creating a high barrier to entry for new firms. The strict regulatory standards for (cGMP) can create production bottlenecks, slowing down the development and commercialization of new gene therapies and vaccines.
Enzymatic DNA Synthesis Technology
Overcoming the limitations of traditional phosphoramidite chemistry, specifically by producing longer, higher-purity DNA strands with improved efficiency. By leveraging biological enzymes like TdT, this approach allows for faster synthesis cycles and reduced reliance on hazardous solvents, which lowers operational costs and supports sustainable, greener manufacturing practices. This technology is transforming the industry from traditional methods to faster, automated, and more cost-effective solutions tailored for synthetic biology, vaccine development, and gene therapy applications.
Why Did the Plasmid DNA Segment Hold a 62% Share for the DNA Manufacturing Market?
The plasmid DNA segment held a dominant position in the market with a share of 62% in 2025. Owing to its critical role in cell and gene therapy manufacturing, and its established use in biopharmaceutical production pipelines. The increasing outsourcing of pDNA manufacturing to specialized contract development and manufacturing to specialized contract development and manufacturing organizations is scaling capacity to meet demand.
The synthetic DNA segment held a 38% share of the market in 2025, and the growing demand for precision medicine, synthetic biology, and customized therapeutics is accelerating adoption. The industry is shifting away from natural DNA isolation toward synthesizing novel proteins, enzymes, and custom genetic constructs for applications in biotechnology and healthcare.
Why Did the GMP Grade Segment Lead the DNA Manufacturing Market?
The GMP grade segment registered its dominance over the market with a share of 68% in 2025, owing to the regulatory-approved therapies requiring GMP-compliant DNA for safety and quality assurance. Increased adoption of mRNA technologies, which require specialized, high-purity DNA templates, bolstered the need for GMP-compliant manufacturing.
The R&D grade segment held the 32% share of the market in 2025, with the use in commercial-scale manufacturing and clinical applications. The rapidly expanding pipelines of preclinical therapeutics require a vast amount of DNA for proof-of-concept studies before moving to clinical trials.
Why Did the Cell & Gene Therapy Segment Lead the DNA Manufacturing Market?
The cell & gene therapy segment registered its dominance over the market with a share of 42% in 2025, owing to the rapid expansion of gene therapy pipelines and increasing approvals of advanced therapies. The surge in clinical trials and commercialization of treatments for cancers and rare, inherited diseases necessitated large-scale manufacturing.
The vaccines screening segment held the 28% share of the market in 2025, with the continued investment in rapid-response vaccine technologies and infectious disease preparedness. Increases investment in cancer immunotherapies and infectious disease solutions, supported by government funding driven up the volume of DNA-based research.
The oligonucleotide-based drugs segment held the 20% share of the market in 2025, due to the rising adoption of precision genetic medicines and RNA-based therapeutics, which is fueling growth. The ability to produce high-quality oligonucleotides quickly and efficiently using solid-phase synthesis has encouraged pharmaceutical companies to invest in these technologies.
The others segment held the 10% share of the market in 2025, with the commercial investment remaining concentrated in therapeutic and vaccine-related applications. Academic institutions and reference labs heavily utilize these customized and specialized DNA products to support research and development and pilot studies.
Why Did the Pharmaceutical and Biotechnology Companies Segment Lead the DNA Manufacturing Market?
The pharmaceutical and biotechnology companies segment registered its dominance over the market with a share of 58% in 2025, owing to extensive investment in gene therapies, biologics, and large-scale DNA manufacturing capacity. The rapid expansion of mRNA platforms has been accelerated by the sustained need for high-throughput DNA manufacturing.
The academic & research institutes segment held the 27% share of the market in 2025, with the increased government and institutional funding for genomic and synthetic biology research supporting growth. The growing use of specialized CROs and CDMOs by academic researchers for custom DNA synthesis and sequencing needs.
The contract research organization segment held the 15% share of the market in 2025, due to the many leading companies maintaining in-house manufacturing for critical therapeutic programs. The surge in cell and gene therapy clinical trials necessitates, with many therapies requiring specialized, large-scale DNA synthesis, that specialized CDMOs can manage effectively.
Why Did the North America Region Lead the DNA Manufacturing Market?
The North America region registered its dominance over the market with a share of 41% in 2025, owing to the high R&D spending, strong presence of biotech companies, and favorable regulatory support for gene therapies. The growing focus on tailored treatments requires custom DNA synthesis, a sector that leads in innovation and capacity.
The Europe region held the 29% share of the market in 2025, due to the strong pharmaceutical manufacturing and government-backed biotech initiatives. The increasing partnership and capacity expansion by contract development and manufacturing organizations in the region.
The Asia Pacific segment held 21% share of the market in 2025, due to the rising genomic research, lower manufacturing costs, and increasing biopharma production in China, Japan, and India. Increasing clinical trials for cancer and rare genetic diseases, growing demand for mRNA vaccines, drive the need for high-quality DNA.
The Latin America region held 5% share of the market in 2025, with the surging demand for cell therapies and a rapidly growing diagnostic sector. Increased investment in infrastructure, combined with regulatory harmonization initiatives, is accelerating market access for local biologics and high-quality DNA plasmid production.
The MEA region held 4% share of the market in 2025, due to the heavily investing in national genome programs to foster personalized medicine, which requires high-quality DNA for testing and therapies. Significant government spending aimed at building local biopharmaceutical manufacturing capabilities is reducing reliance on imports and fostering growth in regional contract manufacturing organizations.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has segmented the DNA manufacturing market.
By Type
By Grade
By Application
By End Use
By Regional
DNA Manufacturing Market
Download Sample
Request Customization
Request Customization
Download Sample